Can integrative biomarker approaches improve prediction of platinum and PARP inhibitor response in ovarian cancer? - ScienceDirect
Current Ovarian Cancer Maintenance Strategies and Promising New Developments
Synergistic Effects of Olaparib and DNA-damaging Agents in Oesophageal Squamous Cell Carcinoma Cell Lines | Anticancer Research
Pharmacological ascorbate induces 'BRCAness' and enhances the effects of Poly(ADP‑Ribose) polymerase inhibitors against BRCA1/2 wild‑type ovarian cancer
Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database - The Lancet Haematology
Cancers | Free Full-Text | Cytotoxicity and Differentiating Effect of the Poly(ADP-Ribose) Polymerase Inhibitor Olaparib in Myelodysplastic Syndromes | HTML
An Overview of PARP Inhibitors for the Treatment of Breast Cancer | SpringerLink
Role of PARP Inhibitors in BRCA-Related Malignancies
Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib - Annals of Oncology
Pharmacological ascorbate induces 'BRCAness' and enhances the effects of Poly(ADP‑Ribose) polymerase inhibitors against BRCA1/2 wild‑type ovarian cancer
Synergistic Effects of Olaparib and DNA-damaging Agents in Oesophageal Squamous Cell Carcinoma Cell Lines | Anticancer Research
Olaparib as maintenance therapy in patients with BRCA 1–2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome - Gynecologic Oncology
Cancers | Free Full-Text | Cytotoxicity and Differentiating Effect of the Poly(ADP-Ribose) Polymerase Inhibitor Olaparib in Myelodysplastic Syndromes | HTML
The Combination of the PARP Inhibitor Olaparib and the WEE1 Inhibitor AZD1775 as a New Therapeutic Option for Small Cell Lung Cancer | Clinical Cancer Research
Cancers | Free Full-Text | Cytotoxicity and Differentiating Effect of the Poly(ADP-Ribose) Polymerase Inhibitor Olaparib in Myelodysplastic Syndromes | HTML
Cancers | Free Full-Text | Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer | HTML
Can integrative biomarker approaches improve prediction of platinum and PARP inhibitor response in ovarian cancer? - ScienceDirect
IJMS | Free Full-Text | Differences in PARP Inhibitors for the Treatment of Ovarian Cancer: Mechanisms of Action, Pharmacology, Safety, and Efficacy | HTML
Pharmacological ascorbate induces 'BRCAness' and enhances the effects of Poly(ADP‑Ribose) polymerase inhibitors against BRCA1/2 wild‑type ovarian cancer
A phase I/II trial of olaparib tablet in combination with eribulin in Japanese patients with advanced or metastatic triple-negative breast cancer previously treated with anthracyclines and taxanes - European Journal of Cancer
Genes | Free Full-Text | MET Expression and Cancer Stem Cell Networks Impact Outcome in High-Grade Serous Ovarian Cancer | HTML
Olaparib as maintenance therapy in patients with BRCA 1–2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome - ScienceDirect
The Combination of the PARP Inhibitor Olaparib and the WEE1 Inhibitor AZD1775 as a New Therapeutic Option for Small Cell Lung Ca
Entinostat, a selective HDAC1/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer - ScienceDirect
Can integrative biomarker approaches improve prediction of platinum and PARP inhibitor response in ovarian cancer? - ScienceDirect
